MPWT
AIMT

MassMutual Private Wealth & Trust’s Aimmune Therapeutics AIMT Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-33
Closed -$789 – 1034
2018
Q4 		$789 Hold
33
– – ﹤0.01% 915
2018
Q3 		$900 Hold
33
– – ﹤0.01% 905
2018
Q2 		$887 Hold
33
– – ﹤0.01% 1022
2018
Q1 		$1.05K Hold
33
– – ﹤0.01% 917
2017
Q4 		$1.25K Buy
+33
New +$1.06K ﹤0.01% 812

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

MassMutual Private Wealth & Trust's AIMT Position: Q1 2019 in Review

MassMutual Private Wealth & Trust sold out of Aimmune Therapeutics (AIMT) in Q1 2019, closing a stake of 33 shares — an estimated $789 sold.

MassMutual Private Wealth & Trust first reported a position in AIMT in Q4 2017 and held it in 5 quarters. The position peaked at $1.25K in Q4 2017. 125 funds tracked by Wall St. Rank hold AIMT as of Q1 2019.

  • MassMutual Private Wealth & Trust reported no remaining Aimmune Therapeutics position as of Q1 2019 after selling out during the quarter.
  • MassMutual Private Wealth & Trust sold 33 Aimmune Therapeutics shares in Q1 2019, an estimated $789.
  • MassMutual Private Wealth & Trust first reported a position in Aimmune Therapeutics in Q4 2017 and held it in 5 quarters.
  • MassMutual Private Wealth & Trust's Aimmune Therapeutics position peaked at $1.25K in Q4 2017.
  • 125 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2019.

Based on MassMutual Private Wealth & Trust's 13F filing for Q1 2019, filed 15 May 2019.